US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

24.82

+0.27001.10%

Post-market: 25.000.1800+0.73%16:35 EDT

Volume:12.52K

Turnover:308.51K

Market Cap:55.72M

PE:- -

High:25.15

Open:24.50

Low:24.35

Close:24.55

52wk High:27.02

52wk Low:15.63

Shares:2.24M

Float Shares:2.24M

Volume Ratio:0.27

T/O Rate:0.56%

Dividend:1.70

Dividend Rate:6.86%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Atea Pharmaceuticals reports C-BEYOND trial meets primary, secondary endpoints

Alkermes Q2 Sales $496.009M Beat $457.818M Estimate

Benzinga Earnings

Press Release: Alkermes Plc Reports Second Quarter 2026 Financial Results

Alkermes Plc : Piper Sandler Raises Target Price to $65 from $43

THOMSON REUTERS

Greenvale Energy Plans Major Share and Option Issue to Boost Capital Base

Compass Pathways PLC Expected to Post a Loss of 40 Cents a Share - Earnings Preview

Compass Pathways Initiated at Equal-Weight by Wells Fargo

Wells Fargo Initiates COMPASS Pathways at Equalweight

MT Newswires Live

Compass Pathways initiated with an Equal Weight at Wells Fargo

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Celldex (CLDX)

Bristol-Myers Squibb Advances New Lung Cancer Combo Into Phase 2: What Investors Should Watch

Takeda’s Elritercept Trial Targets Anemia in Myelofibrosis, Raising Long-Term Upside for TAK

Jazz Pharmaceuticals Advances Phase 3 Cannabidiol Trial in Severe Childhood Epilepsy

Organon to present results from analysis of Phase 3 trials of VTAMA cream

Radiopharm outlines capital raising plans and risk warnings for oncology radiopharma platform

Lightning Minerals shareholders back all capital raising resolutions

Kringle Pharma Launches Additional Phase 3 Trial of Oremepermin Alfa in Acute Spinal Cord Injury

X2M Connect Plans Major Share and Option Issue on ASX

Dalaroo board backs A$1.75m raising to drive gold and rare earths push

Verastem doses first patient in TARGET-D 202 Phase 2 trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/PSIL/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":24.82,"timestamp":1788379200000,"preClose":24.55,"halted":0,"volume":12522,"hourTrading":{"tag":"盘后","latestPrice":25,"preClose":24.82,"latestTime":"16:35 EDT","volume":18,"amount":446.41998,"timestamp":1788381359320,"change":0.18,"changeRate":0.007252,"amplitude":0.012893},"delay":0,"changeRate":0.010997963340122182,"floatShares":2244976,"shares":2244976,"eps":0,"marketStatus":"Post-Mkt","change":0.27,"latestTime":"09-02 16:36:23 EDT","open":24.5,"high":25.145,"low":24.3501,"amount":308505.45315,"amplitude":0.032379,"askPrice":26.26,"askSize":12,"bidPrice":24.68,"bidSize":1,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788393600000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":24.55,"sharesOutstanding":1184976,"nav":24.77,"aum":55609064.46,"dividendRate":0.068638,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":24.8,"preClose":24.55,"latestTime":"08:30 EDT","volume":22,"amount":539.989956,"timestamp":1788352229605,"change":0.25,"changeRate":0.010183,"amplitude":0.013035},"postHourTrading":{"tag":"盘后","latestPrice":25,"preClose":24.82,"latestTime":"16:35 EDT","volume":18,"amount":446.41998,"timestamp":1788381359320,"change":0.18,"changeRate":0.007252,"amplitude":0.012893},"volumeRatio":0.274974,"impliedVol":0.4809,"impliedVolPercentile":0.8651},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2244976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.274974,"shares":2244976,"dividePrice":1.7036,"high":25.145,"amplitude":0.032379,"preClose":24.55,"low":24.3501,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":24.82,"committee":-0.846154,"eps":0,"divideRate":0.068638,"volume":12522,"delay":0,"ttmEps":0,"open":24.5,"prevYearClose":17.17,"prevWeekClose":25.2464,"prevMonthClose":24.62,"prevQuarterClose":24.05,"fiveDayClose":26.33,"twentyDayClose":24.66,"sixtyDayClose":19.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2654009645","title":"Atea Pharmaceuticals reports C-BEYOND trial meets primary, secondary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2654009645","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654009645?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:21","pubTimestamp":1785237677,"startTime":"0","endTime":"0","summary":"Atea Pharmaceuticals (AVIR) announced topline results from C-BEYOND, its Phase 3 trial conducted in North America evaluating the once-daily fixed-d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atea-pharmaceuticals-reports-c-beyond-trial-meets-primary-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atea-pharmaceuticals-reports-c-beyond-trial-meets-primary-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVIR","PSIL","BK4007","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654006162","title":"Alkermes Q2 Sales $496.009M Beat $457.818M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2654006162","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654006162?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:02","pubTimestamp":1785236572,"startTime":"0","endTime":"0","summary":"Alkermes (NASDAQ:ALKS) reported quarterly sales of $496.009 million which beat the analyst consensus estimate of $457.818 million by 8.34 percent.  This is a 26.97 percent increase over sales of $390.657 million the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/07/60719288/alkermes-q2-sales-496-009m-beat-457-818m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","FBT","PSIL","MEDX","ALKS","PSCH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654006923","title":"Press Release: Alkermes Plc Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2654006923","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654006923?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:00","pubTimestamp":1785236400,"startTime":"0","endTime":"0","summary":"DUBLIN--(BUSINESS WIRE)--July 28, 2026--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press releas","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","FBT","MEDX","PSCH","ADHD","ALKS","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654502005","title":"Alkermes Plc : Piper Sandler Raises Target Price to $65 from $43","url":"https://stock-news.laohu8.com/highlight/detail?id=2654502005","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654502005?lang=en_us&edition=fundamental","pubTime":"2026-07-28 12:05","pubTimestamp":1785211555,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43T1LE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","IBRN","ALKS","PSIL","FBT","BK4139","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654002919","title":"Greenvale Energy Plans Major Share and Option Issue to Boost Capital Base","url":"https://stock-news.laohu8.com/highlight/detail?id=2654002919","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654002919?lang=en_us&edition=fundamental","pubTime":"2026-07-28 07:50","pubTimestamp":1785196211,"startTime":"0","endTime":"0","summary":"Greenvale Mining ( ($AU:GRV) ) has provided an update. Greenvale Energy Ltd has notified the ASX of a proposed capital raising via a placement and ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/greenvale-energy-plans-major-share-and-option-issue-to-boost-capital-base?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/greenvale-energy-plans-major-share-and-option-issue-to-boost-capital-base?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654436048","title":"Compass Pathways PLC Expected to Post a Loss of 40 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2654436048","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654436048?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:03","pubTimestamp":1785157388,"startTime":"0","endTime":"0","summary":"Compass Pathways PLC <CMPS.OQ> expected to post a loss of40cents a share - Earnings PreviewCompass Pathways PLCCMPS.OQCMPS.Ois expected to  show no change in quarterly revenue when it reports  results","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL8N43T154:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654485310","title":"Compass Pathways Initiated at Equal-Weight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2654485310","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654485310?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:52","pubTimestamp":1785156720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CMPS/analyst-ratings(END) Dow Jones NewswiresJuly 27, 2026 08:52 ET","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0868494708.USD","LU0314106906.USD","LU0208291251.USD","LU0477156953.USD","LU1069347547.HKD","BK4501","LU0251142724.SGD","LU0128525929.USD","LU1894683348.USD","BK4585","IYF","LU0971096721.USD","LU0310799852.SGD","LU1267930227.SGD","LU1506573853.SGD","FTXO","LU0708994859.HKD","LU0980610538.SGD","IE0002270589.USD","LU0289960550.SGD","LU1267930490.SGD","IE00B19Z3581.USD","LU0683600562.USD","TFNS","PSIL","BK4139","CMPS","LU0070302665.USD","LU2361045086.USD","LU1280957306.USD","LU0048573561.USD","LU0128525689.USD","LU0251131958.USD","BK4582","LU2361044865.SGD","LU2361044949.HKD","PGF","LU0256863811.USD","LU0417517546.SGD","LU0648001328.SGD","LU1201861249.SGD","LU0052756011.USD","LU1668664300.SGD","LU1791807156.HKD","IE000M9KFDE8.USD","LU0310800379.SGD","LU0029864427.USD","KBWB","LU0072461881.USD","LU0130517989.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654017757","title":"Wells Fargo Initiates COMPASS Pathways at Equalweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2654017757","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654017757?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:12","pubTimestamp":1785154373,"startTime":"0","endTime":"0","summary":"COMPASS Pathways (CMPS) has an average rating of buy and mean price target of $22.86, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0310800965.SGD","LU0130102774.USD","BK4501","LU2361044865.SGD","KBWB","BK4559","LU0052756011.USD","LU0417517546.SGD","WFC","LU0320765489.SGD","PGF","LU2361045086.USD","TFNS","LU0070302665.USD","LU0128525929.USD","IYF","LU0648001328.SGD","IE000M9KFDE8.USD","LU0048573561.USD","BK4207","LU0868494617.USD","LU1280957306.USD","CMPS","LU0072461881.USD","LU1074936037.SGD","LU1814569148.SGD","LU1894683264.USD","BK4588","BK4585","LU1506573853.SGD","LU0106831901.USD","LU0251142724.SGD","LU2236285917.USD","LU1069347547.HKD","LU0683600562.USD","LU1267930573.SGD","LU0211327993.USD","LU0787776722.HKD","BK4139","PSIL","LU1201861249.SGD","LU0267386448.USD","FTXO","LU2361044949.HKD","LU0162691827.USD","LU1791807156.HKD","LU0211328371.USD","LU0708994859.HKD","LU2461242641.AUD","LU0314106906.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654016997","title":"Compass Pathways initiated with an Equal Weight at Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2654016997","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654016997?lang=en_us&edition=fundamental","pubTime":"2026-07-27 17:25","pubTimestamp":1785144306,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Benjamin Burnett initiated coverage of Compass Pathways (CMPS) with an Equal Weight rating and $13 price target While the two p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/compass-pathways-initiated-with-an-equal-weight-at-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/compass-pathways-initiated-with-an-equal-weight-at-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0310799852.SGD","KBWB","FTXO","LU2361044865.SGD","LU2361045086.USD","LU0640476718.USD","IE00B19Z3581.USD","LU1894683348.USD","LU2461242641.AUD","LU1894683264.USD","BK4582","LU0971096721.USD","LU2236285917.USD","BK4139","BK4207","IYF","LU1267930227.SGD","PSIL","LU0256863811.USD","IE000M9KFDE8.USD","LU1035773651.USD","LU0048573561.USD","LU1267930490.SGD","LU1363072403.SGD","LU0314106906.USD","LU0072461881.USD","LU0320765489.SGD","IE0002270589.USD","LU0130102774.USD","BK4501","LU0310800379.SGD","CMPS","LU1069347547.HKD","LU1668664300.SGD","TFNS","LU0175139822.USD","LU0029864427.USD","LU0211328371.USD","BK4585","LU1267930573.SGD","LU1791807156.HKD","LU0251142724.SGD","LU0742534661.SGD","LU0683600562.USD","PGF","LU1201861249.SGD","LU0942090050.USD","LU1074936037.SGD","BK4559","LU0417517546.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654054554","title":"Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654054554","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654054554?lang=en_us&edition=fundamental","pubTime":"2026-07-25 22:50","pubTimestamp":1784991019,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alkermes (ALKS) and Celldex (CLDX) with bullish sent...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-and-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-and-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","LU0128526141.USD","LABU","FBT","HCSG","LU0029874061.USD","MEDX","BK4139","XLV","PSCH","BK4581","IBRN","BK4137","XBI","CLDX","ALKS","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654036222","title":"Bristol-Myers Squibb Advances New Lung Cancer Combo Into Phase 2: What Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2654036222","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654036222?lang=en_us&edition=fundamental","pubTime":"2026-07-25 00:34","pubTimestamp":1784910898,"startTime":"0","endTime":"0","summary":"Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb is running a Phase 2 trial to test a ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bristol-myers-squibb-advances-new-lung-cancer-combo-into-phase-2-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bristol-myers-squibb-advances-new-lung-cancer-combo-into-phase-2-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0114720955.EUR","LU1093756168.USD","LU1868836757.USD","IE00BSNM7G36.USD","BK4585","BK4581","LU0321505439.SGD","LU2125154778.USD","BK4211","LU1093756325.SGD","BMY","BBC","LU1983299246.USD","LU2125154935.USD","LU0456855351.SGD","LU1585245621.USD","FTXH","LU1670710661.SGD","LU2242646821.SGD","LU1261432733.SGD","LU1868836914.USD","LU1291159041.SGD","LU0432979614.USD","LU1323610961.USD","LU0237698245.USD","LU1074936037.SGD","IE00BFTCPJ56.SGD","IE00BFXG1179.USD","BK4532","LU0225771236.USD","LU1868837136.USD","LU0267386448.USD","BK4007","LU0061475181.USD","LU0306807586.USD","PSIL","IHE","LU1670711040.USD","IE00B2B36J28.USD","LU1868836591.USD","ISBC","LU0985481810.HKD","BK4534","LU0882574055.USD","LU0306806265.USD","LU0225284248.USD","IE00BJJMRZ35.SGD","LU0321505868.SGD","BK4588","LU1670710588.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654362520","title":"Takeda’s Elritercept Trial Targets Anemia in Myelofibrosis, Raising Long-Term Upside for TAK","url":"https://stock-news.laohu8.com/highlight/detail?id=2654362520","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654362520?lang=en_us&edition=fundamental","pubTime":"2026-07-25 00:34","pubTimestamp":1784910878,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Company ($TAK) announced an update on their ongoing clinical study. Takeda is running a Phase 3 trial to test elritercept (TA...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takedas-elritercept-trial-targets-anemia-in-myelofibrosis-raising-long-term-upside-for-tak?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takedas-elritercept-trial-targets-anemia-in-myelofibrosis-raising-long-term-upside-for-tak?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BK4007","TAK","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654036255","title":"Jazz Pharmaceuticals Advances Phase 3 Cannabidiol Trial in Severe Childhood Epilepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2654036255","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654036255?lang=en_us&edition=fundamental","pubTime":"2026-07-25 00:33","pubTimestamp":1784910829,"startTime":"0","endTime":"0","summary":"Jazz Pharmaceuticals ($JAZZ) announced an update on their ongoing clinical study. Jazz Pharmaceuticals is preparing a Phase 3 trial to test a new o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/jazz-pharmaceuticals-advances-phase-3-cannabidiol-trial-in-severe-childhood-epilepsy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/jazz-pharmaceuticals-advances-phase-3-cannabidiol-trial-in-severe-childhood-epilepsy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653204084","title":"Organon to present results from analysis of Phase 3 trials of VTAMA cream","url":"https://stock-news.laohu8.com/highlight/detail?id=2653204084","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653204084?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:11","pubTimestamp":1784895078,"startTime":"0","endTime":"0","summary":"Organon (OGN) will present results from a post hoc analysis of pooled data from the Phase 3 pivotal trials, ADORING 1 and ADORING 2, evaluating the...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/organon-to-present-results-from-analysis-of-phase-3-trials-of-vtama-cream-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/organon-to-present-results-from-analysis-of-phase-3-trials-of-vtama-cream-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","FXH","LU2065169927.USD","LU2065171311.SGD","OGN","BK4585","BBC","BK4007","LU2065171402.SGD","LU2065170008.USD","BK4559","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653702156","title":"Radiopharm outlines capital raising plans and risk warnings for oncology radiopharma platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2653702156","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653702156?lang=en_us&edition=fundamental","pubTime":"2026-07-24 15:38","pubTimestamp":1784878698,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Radiopharm Theranostics Limited ( ($AU:RAD) ). Radiopharm Theranostics has released a capital raising presentat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/radiopharm-outlines-capital-raising-plans-and-risk-warnings-for-oncology-radiopharma-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/radiopharm-outlines-capital-raising-plans-and-risk-warnings-for-oncology-radiopharma-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653063997","title":"Lightning Minerals shareholders back all capital raising resolutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2653063997","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653063997?lang=en_us&edition=fundamental","pubTime":"2026-07-24 13:03","pubTimestamp":1784869393,"startTime":"0","endTime":"0","summary":"An announcement from Lightning Minerals Ltd. ( ($AU:L1M) ) is now available. Lightning Minerals Ltd shareholders approved all resolutions put forwa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lightning-minerals-shareholders-back-all-capital-raising-resolutions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lightning-minerals-shareholders-back-all-capital-raising-resolutions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","MTX","BK4109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653708145","title":"Kringle Pharma Launches Additional Phase 3 Trial of Oremepermin Alfa in Acute Spinal Cord Injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2653708145","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653708145?lang=en_us&edition=fundamental","pubTime":"2026-07-24 10:52","pubTimestamp":1784861536,"startTime":"0","endTime":"0","summary":"Kringle Pharma, Inc. ( ($JP:4884) ) has shared an announcement. Kringle Pharma has launched an additional Phase 3 trial in Japan to evaluate oremep...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kringle-pharma-launches-additional-phase-3-trial-of-oremepermin-alfa-in-acute-spinal-cord-injury?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kringle-pharma-launches-additional-phase-3-trial-of-oremepermin-alfa-in-acute-spinal-cord-injury?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BK4135","JP","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653772545","title":"X2M Connect Plans Major Share and Option Issue on ASX","url":"https://stock-news.laohu8.com/highlight/detail?id=2653772545","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653772545?lang=en_us&edition=fundamental","pubTime":"2026-07-24 08:08","pubTimestamp":1784851687,"startTime":"0","endTime":"0","summary":"The latest update is out from X2M Connect Limited ( ($AU:X2M) ). X2M Connect Limited has notified the ASX of a proposed capital raising involving t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/x2m-connect-plans-major-share-and-option-issue-on-asx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/x2m-connect-plans-major-share-and-option-issue-on-asx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653399774","title":"Dalaroo board backs A$1.75m raising to drive gold and rare earths push","url":"https://stock-news.laohu8.com/highlight/detail?id=2653399774","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653399774?lang=en_us&edition=fundamental","pubTime":"2026-07-24 06:44","pubTimestamp":1784846651,"startTime":"0","endTime":"0","summary":"Dalaroo Metals Ltd. ( ($AU:DAL) ) has shared an announcement. Dalaroo Metals has completed the second tranche of a capital raising, securing about ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dalaroo-board-backs-a1-75m-raising-to-drive-gold-and-rare-earths-push?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dalaroo-board-backs-a1-75m-raising-to-drive-gold-and-rare-earths-push?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PICK","JDST","MVPS","FGDL","GLDM","PSIL","DUST","SHNY","BAR","DBC","GLTR","1OZmain","USG","GLL","IAUM","UYM","YGLD","REMX","GDX","OUNZ","BTGD","DAL","GDXD","DZZ","SGOL","GOAU","GDXJ","CRIT","DGZ","IAUI","RING","JNUG","XME","DULL","PPI","PHYS","FXZ","GDXU","UGL","AAAU","BEGS","GLD","GDXY","SGDM","GBUG","GOLY","JETS","IAU","DGP","CEF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653939797","title":"Verastem doses first patient in TARGET-D 202 Phase 2 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653939797","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653939797?lang=en_us&edition=fundamental","pubTime":"2026-07-23 04:06","pubTimestamp":1784750793,"startTime":"0","endTime":"0","summary":"Verastem (VSTM) Oncology announced that the first patient has been dosed in the TARGET-D 202 Phase 2 registration-directed trial evaluating VS-7375...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/verastem-doses-first-patient-in-target-d-202-phase-2-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/verastem-doses-first-patient-in-target-d-202-phase-2-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PSIL","BBC","VSTM"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}]}}